ad image

ABL Bio

1 / 1
WuXi Biologics
Immuno-Oncology

ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million

WuXi Biologics

PR-M02-19-NI-067Feb 28, 2019
WuXi Biologics
Partnership

WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies

WuXi Biologics

PR-M12-18-NI-003Dec 03, 2018
ABL Bio
Global Collaboration

ABL Bio and I-Mab Biopharma Announce Global Collaboration on Innovative Bispecific Antibodies

ABL Bio

PR-M08-18-NI-005Aug 01, 2018
I-Mab
Global Collaboration

I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies

I-Mab

PR-M07-18-NI-107Jul 31, 2018
1 / 1